ClinicalTrials.gg
RecruitingNCT05445804Updated Jan 7, 2026

Oral Cannabidiol for Tobacco Cessation

A Phase 1 interventional study of 300 mg Cannabidiol and 600 mg Cannabidiol in Tobacco Use, Tobacco Smoking and Tobacco Dependence, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Primary conditionTobacco SmokingRegistry: Tobacco UseReclassifiedWhy we changed it
Registry
Tobacco Use — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tobacco Smoking
Why
  1. The study's listed conditions name Tobacco Smoking, a narrower term within Tobacco Use.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Johns Hopkins University · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Tobacco Smoking by Johns Hopkins University — 2 open to participants now, 2 under way, none of them phase 3. Tobacco Smoking · Johns Hopkins University.

Planned enrollment
5th of 10
50 · median 44
Started
2022
the only one that year
Phase 1
3 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Tobacco Smoking by Johns Hopkins University, this one is the 5th largest by planned enrollment, is the only one that started in 2022, is one of 3 in phase 1, and was the 9th registered.

Tobacco Smoking

265 studies on the registry are indexed under Tobacco Smoking; 43 are open to participants now.

Browse Tobacco Smoking studies →

Open to participants now

2 of the 10 studies in Tobacco Smoking by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 34 Tobacco Smoking studies recruiting now, 15 (44%) set no upper age limit and 17 (50%) stop at 75 or younger; 2 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Tobacco Smoking by Johns Hopkins University, or all of them as a file.
02

Study summary

Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabidiol for tobacco cessation.

Read the detailed description

Although tobacco smoking rates continue to decrease, cigarette smoking remains the leading cause of preventable disease and death in the United States and few tobacco users achieve sustained abstinence, underscoring the need for alternative treatments. The endocannabinoid system can modulate the reinforcing effects of nicotine and may be a target for development of pharmacotherapies for tobacco cessation. The cannabinoid type 1 receptor receptor inverse agonist/antagonist rimonabant has demonstrated efficacy in increasing tobacco abstinence rates in clinical trials, though it was abandoned as a viable medication due to adverse psychiatric side effects. Compounds that have similar pharmacology to rimonabant, but without the adverse psychiatric side effect profile may be efficacious for tobacco cessation. Cannabidiol (CBD) is a naturally occurring constituent of the cannabis plant that has been well tolerated in clinical studies and has low abuse liability. CBD has demonstrated anxiolytic, antipsychotic, and antidepressant effects, and can reduce appetite, suggesting that it may reduce known nicotine withdrawal symptoms associated with relapse. One clinical study provided initial evidence that CBD may be useful to promote tobacco cessation, however, the mechanism by which smoking was reduced is not clear and appropriate dosing remains unknown.

This research will apply a rigorous methodological approach as an early screener for potential pharmacotherapies for tobacco dependence. This approach will utilize systematic dose administration and biochemical verification of smoking abstinence to evaluate CBD as a potential pharmacotherapy for tobacco cessation. A double-blind, within-subject, double-crossover design will be used to compare the effect of twice-daily oral CBD and matched placebo on short-term tobacco abstinence, and explore potential mechanisms underlying the effect of CBD on tobacco withdrawal, negative affect, and reinforcement.

03

Conditions studied

  • Tobacco Use
  • Tobacco Smoking
  • Tobacco Dependence
  • Tobacco Use Disorder
  • Tobacco Use Cessation

Keywords

  • Tobacco
  • Smoking
  • Cannabidiol
  • CBD
04

In context

Tobacco Smoking Reclassified

265 studies on the registry are indexed under Tobacco Smoking; 43 are open to participants now.

This study's planned enrollment of 50 is below the median of 120 across 230 interventional studies indexed under Tobacco Smoking.

Browse Tobacco Smoking studies →

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.

Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.

Compared within Tobacco Smoking, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tobacco Use. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have provided written
  2. Be between the ages of 18 and 65
  3. Report use of > 10 cigarettes per day for > 1 year with smoking status verified by either a positive breath carbon monoxide test (>8ppm) or urine cotinine test (>200ng/mL) at screening
  4. Report interest in quitting tobacco in the next two months
  5. Are willing to engage in a series of practice quit attempts as part of the study.
  6. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests as determined by a licensed medical professional.
  7. For women of children bearing potential and men with female partners of , must be willing to use an effective form of during the study and for at least 30 days after the last study drug administration. Acceptable forms of contraception include: double barrier contraception or a combination of a barrier contraception and a hormonal implant, injectable, combined oral contraceptive, or a male partner who has had a vasectomy; intrauterine device or tubal ligation.

Exclusion criteria

Exclusion Criteria:

  1. Meet Diagnostic and Statistical Manual-V criteria for substance use disorders except for nicotine or tobacco use disorders
  2. Are currently receiving or interested in immediately receiving behavioral treatment or medication for smoking cessation
  3. Test positive for drugs of abuse (except nicotine) and/or breath alcohol test at study admission
  4. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity.
  5. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
  6. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding.
  7. Use of an over the counter, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study results or the safety of the participant
  8. Use of a prescription medication (with the exception of prescriptions) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the participant. This includes any medication metabolized via CYP2D6, CYP2C9, CYP2B10, or which induce/inhibit enzymes.
  9. Have a history of cardiac arrhythmias or vasospastic disease (e.g. Prinzmetal's angina).
  10. Have elevated serum liver transaminase ( or ALT) above 2 x , or elevated above 1.5 x upper limit of normal.
  11. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.

    -

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Within-Subjects Dose Conditions

    All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be counterbalanced across participants. Thus, comparisons of the drug conditions on outcome measures will be compared within-subjects (e.g., between drug and placebo) and not between arms.

    Drug: 300 mg Cannabidiol · Drug: 600 mg Cannabidiol · Drug: Placebo

  • Experimental
    Additional Within-Subjects Dose Conditions

    All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be counterbalanced across participants. Thus, comparisons of the drug conditions on outcome measures will be compared within-subjects (e.g., between drug and placebo) and not between arms.

    Drug: 300 mg Cannabidiol · Drug: 600 mg Cannabidiol · Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. biochemically-verified tobacco abstinence as assessed by expired carbon monoxide

    Biochemically-verified tobacco abstinence as assessed by expired carbon monoxide part per million during the 4-day practice quit attempt of each drug condition.

    Time frame: 4 days

Secondary outcomes

  1. Smoking Puff Topography

    smoking puff topography will be collected each Monday during simulated quit attempt weeks (2, 4, and 6).

    Time frame: Change between simulated quit attempt (weeks 2, 4, and 6).

  2. Cigarette Purchase Task

    Cigarette Purchase Task will be collected each Monday during simulated quit attempt weeks (2, 4, and 6).

    Time frame: Change between simulated quit attempt (weeks 2, 4, and 6).

  3. Modified Cigarette Evaluation Scale

    Modified Cigarette Evaluation Scale will be collected each Monday during simulated quit attempt weeks (2, 4, and 6).

    Time frame: Change between simulated quit attempt (weeks 2, 4, and 6).

  4. Tobacco Smoking as assessed by self report

    Self-reported cigarettes per day

    Time frame: Change between simulated quit attempt (weeks 2, 4, and 6).

  5. Tobacco Withdrawal as assessed by the Minnesota Nicotine Withdrawal Scale

    Minnesota Nicotine Withdrawal Scale Total Score (range 0 - 36) higher scores equate with greater withdrawal

    Time frame: 2 weeks

  6. Tobacco Withdrawal as assessed by the Questionnaire of Smoking Urges - Brief

    Questionnaire of Smoking Urges - Brief - Ten item questionnaire contains two 5-item factor scores - higher scores equate with greater smoking urge

    Time frame: 2 weeks

  7. Tobacco Withdrawal as assessed by the Positive and Negative Affect Scale

    Positive and Negative Affect Scale - composed of 20 items, 10 measuring positive affect and 10 measuring negative affect. Scores range from 1 to 5 corresponding with extent to which the affect was experienced in the specified timeframe.

    Time frame: 2 weeks

  8. Tobacco Withdrawal as assessed by the Hospital Anxiety and Depression Scale

    Hospital Anxiety and Depression Scale - 14 item assessment of anxiety and depression. Each item measured on a 4-point scale. Higher scores equate with greater depression/anxiety.

    Time frame: 2 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — There is not currently a plan to make individual participant data available to other researchers.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Dec 2026, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 6, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Dec 1, 2026
CompletionEst.
Feb 1, 2027
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05445804
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Nov 1, 2022
Primary completion
Dec 1, 2026 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Jan 7, 2026

Study contacts

Dustin C Lee, PhD
Contact
dlee214@jhmi.edu
410-550-4035
Dustin C Lee, PhD
principal investigator · Behavioral Pharmacology Research Unit, Johns Hopkins Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion